

# Comparison of low dose versus high dose Botulinum toxin (Dysport) in the treatment of children with hemiplegic cerebral palsy.

|  |  |  |
|--|--|--|
| <b>Submission date</b><br>23/01/2004   | <b>Recruitment status</b><br>No longer recruiting    | <input type="checkbox"/> Prospectively registered    |
| <b>Registration date</b><br>23/01/2004 | <b>Overall study status</b><br>Completed             | <input type="checkbox"/> Protocol                    |
| <b>Last Edited</b><br>22/02/2008       | <b>Condition category</b><br>Nervous System Diseases | <input type="checkbox"/> Statistical analysis plan   |
|  |  | <input checked="" type="checkbox"/> Results          |
|  |  | <input type="checkbox"/> Individual participant data |

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Chris Ward

**Contact details**  
Southern Derbyshire Acute Hospitals NHS Trust  
Derby City General Hospital  
Uttoxeter Road  
Derby  
United Kingdom  
DE22 3NE  
+44 (0)1332 340141 Ext 5680  
c.d.ward@nottingham.ac.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

# Study information

## Scientific Title

### Study objectives

Is 24 ng Dysport/Kg body weight more efficacious than 8 ng Dysport/Kg (using impairment measures)

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

### Study type(s)

Treatment

## Participant information sheet

### Health condition(s) or problem(s) studied

Nervous system diseases: Cerebral palsy

### Interventions

1. 24 ng Dysport/kg body weight
2. 8 ng Dysport/kg (using impairment measures)

### Intervention Type

Drug

### Phase

Not Applicable

### Drug/device/biological/vaccine name(s)

Botulinum toxin (Dysport)

**Primary outcome measure**

1. Impairment measure using gait analysis
2. Gastrocnemius muscle length was calculated at each visit using the method described by Eames and used as primary outcome measure

**Secondary outcome measures**

Secondary outcome variable was maximum ankle angle measured during stance and swing phases.

**Overall study start date**

01/03/1997

**Completion date**

31/07/2000

**Eligibility****Key inclusion criteria**

Children with hemiplegic cerebral palsy

**Participant type(s)**

Patient

**Age group**

Child

**Sex**

Both

**Target number of participants**

60

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/03/1997

**Date of final enrolment**

31/07/2000

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**  
Southern Derbyshire Acute Hospitals NHS Trust  
Derby  
United Kingdom  
DE22 3NE

## **Sponsor information**

**Organisation**  
NHS R&D Regional Programme Register - Department of Health (UK)

**Sponsor details**  
The Department of Health  
Richmond House  
79 Whitehall  
London  
United Kingdom  
SW1A 2NL  
+44 (0)20 7307 2622  
dhmail@doh.gsi.org.uk

**Sponsor type**  
Government

**Website**  
<http://www.doh.gov.uk>

## **Funder(s)**

**Funder type**  
Government

**Funder Name**  
NHS Executive Trent (UK)

## **Results and Publications**

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

# Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

| Output type                     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a> | Results | 01/08/2002   |            | Yes            | No              |